Enlarged Board of Appeal rules on double patenting

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Enlarged Board of Appeal rules on double patenting

Sponsored by

maiwald-logo-cropped.PNG
butterflies-1127666-1280-1.jpg

Annelie Wünsche and Stefanie Parchmann of Maiwald discuss double patenting before the EPO

On June 22 2021, the Enlarged Board of Appeal of the European Patent Office issued decision G 4/19 (Double patenting), in which it held that a European patent (EP) application can be refused if it claims the same subject matter as a granted European patent (i.e. not just a co-pending EP application) which has been granted to the same applicant and has the same effective date. 

The application can be refused irrespective of whether it (a) was filed on the same date as, or (b) is a parent application or a divisional application of, or (c) claims the same priority as the European patent already granted.

In other words: if an applicant already achieved grant of an EP patent on a certain subject matter, the Examining Division will deny grant to claims on the ‘same’ subject matter in later examination proceedings pertaining to an application having the same ‘effective date’ as the granted patent.

This even applies if the EP patent that was granted earlier is the priority application of the later-examined application. The advantage of a longer term of protection (due to the later filing date) that is thus lost for the applicant is no justification for allowing double patenting.

The Enlarged Board of Appeal relied on Article 125 EPC, which stipulates that “in the absence of procedural provisions in this Convention, the European Patent Office shall take into account the principles of procedural law generally recognised in the Contracting States”.

Two pieces of the puzzle, however, were deliberately not examined by the Enlarged Board of Appeal. First, even though the referring Board asked for clarification, the concept of ‘same subject matter’ was not addressed (does overlap also count?). Second, the question whether the rules on double patenting will also have to be applied in opposition proceedings remained unanswered.

But we notice that a distinction between ‘double protection’ (claims with overlapping scope) and ‘double patenting’ was made in the Reasons, and we are therefore quite confident that the prohibition of double patenting will remain a prohibition of double patenting in a narrow sense, limited to claims on exactly the ‘same’ invention. Overlapping claims should, therefore, remain admissible.

Thus, tailoring the claims of the later application to a merely overlapping claim scope might still provide the possibility to get the later application granted. It remains to be seen whether filing a request for revocation of the earlier patent will be allowed as a means to address a double patenting situation. 

We are also curious to see whether double patenting rules will now be applied more often in opposition proceedings; at present, applying them is within the discretion of an opposition division. 

 

Annelie Wünsche

Partner, Maiwald 

E: wuensche@maiwald.eu

 

Stefanie Parchmann

Partner, Maiwald 

E: parchmann@maiwald.eu

 

 

more from across site and SHARED ros bottom lb

More from across our site

Anousha Davies, associate and trademark attorney at Birketts, unpicks how the university’s reputation enabled it to see off a proposed trademark for ‘Cambridge Rowing’
IP lawyers, who say they are encouraging clients to build up ‘tariff resilience’, should treat the risks posed by recent orders as a core consideration in cross-border licensing
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
News of Via Licensing Alliance adding two new members and Nokia’s proposal to extend interim licences to Warner Bros Discovery and Paramount were also among the top talking points
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Cooley and Stikeman Elliott advised 35Pharma on the deal, which will allow GSK to get its hands on S235, an investigational medicine for pulmonary hypertension
Simon Wright explains why the UK should embrace the possibility of rejoining the UPC, and reveals how CIPA is reacting to this month’s historic Emotional Perception AI case at the UK Supreme Court
Matthew Grady of Wolf Greenfield says AI presents an opportunity in patent practice for stronger collaboration between in-house and outside counsel
Aparna Watal, head of trademarks at Halfords IP, discusses why lawyers must take a stand when advising clients and how she balances work, motherhood and mentoring
Discussion hosted by Bird & Bird partners also hears that UK courts’ desire to determine FRAND rates could see the jurisdiction penalised in a similar way to China
Gift this article